Compare ROMA & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | PYPD |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.9M | 66.2M |
| IPO Year | 2024 | 2020 |
| Metric | ROMA | PYPD |
|---|---|---|
| Price | $2.32 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 3.3K | ★ 86.0K |
| Earning Date | 12-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,568,345.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $0.58 | $2.30 |
| 52 Week High | $4.66 | $4.07 |
| Indicator | ROMA | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 58.21 |
| Support Level | $2.23 | $3.94 |
| Resistance Level | $2.51 | $4.07 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 41.70 | 68.09 |
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.